Advertisement

Infectious Complications of Oncologic Therapy

  • J. P. Flaherty
Chapter
  • 109 Downloads

Abstract

Infection complicates the treatment of malignancy either as a direct result of the neoplastic process (e.g., postobstructive pneumonia in a patient with lung cancer) or more commonly, as a result of treatment (e.g., Gram-negative sepsis in a neutropenic patient following high-dose chemotherapy). As our understanding of the pathogenesis of infection in cancer patients has grown and the availability of effective antimicrobial therapy has improved, cancer treatment has become more intensive and antimicrobial resistance has kept pace with the development of new antimicrobial agents. The management of infectious complications in oncology patients requires continued vigilance for evidence of infection in susceptible patients, an awareness of trends in emerging antimicrobial resistance, and knowledge of the appropriate place for newer antimicrobial agents.

Keywords

Clin Infect Invasive Aspergillosis Invasive Fungal Infection Neutropenic Patient Febrile Neutropenic Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bodey GP, Buckley M, Sathe YS et al (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328–339PubMedGoogle Scholar
  2. 2.
    Hughes WT, Armstrong D, Bodey GP et al (1997) Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 25:551–573PubMedCrossRefGoogle Scholar
  3. 3.
    Sickles EA, Greene WH, Wiernik PH (1975) Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 64:328–339Google Scholar
  4. 4.
    Donowitz GR, Harmon C, Pope T, Stewart FM (1991) The role of the chest roentgenogram in febrile, neutropenic patients. Arch Intern Med 151:701–704PubMedCrossRefGoogle Scholar
  5. 5.
    Sanders JW, Powe NR, Moore RD (1991) Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a meta-analysis. J Infect Dis 164:907–916PubMedCrossRefGoogle Scholar
  6. 6.
    De Pauw BE, Deresinski SC, Feld R et al (1994) Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. Ann Intern Med 120:834–844PubMedGoogle Scholar
  7. 7.
    Freifeld AG, Walsh T, Marshall D et al (1995) Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 13:165–176PubMedGoogle Scholar
  8. 8.
    Rolston KVI, Berkey P, Bodey GP et al (1992) A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 152:283–291PubMedCrossRefGoogle Scholar
  9. 9.
    Chandrasekar PH, Arnow PA (2000) Cefepime versus ceftazidime as empiric therapy for fever in neutropenic patients with cancer. Ann Pharmacother 34:989–995PubMedCrossRefGoogle Scholar
  10. 10.
    Feld R, DePauw B, Berman S, Keating A, Winston H (2000) Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomised, doubleblind trial. J Clin Oncol 18:3690–3698PubMedGoogle Scholar
  11. 11.
    Giamarellou H, Bassaris HP, Petrikkos G et al (2000) Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic pateints with fever. Antimicrob Agents Chemother 44:3264–3271PubMedCrossRefGoogle Scholar
  12. 12.
    Cometta A, Zinner S, DeBock R et al (1995) Piperacillintazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 39: 445–452PubMedCrossRefGoogle Scholar
  13. 13.
    Cordonnier C, Herbrecht R, Pico JL et al (1997) Cefepime/ amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients; a comparative study. Clin Infect Dis 24:41–51PubMedCrossRefGoogle Scholar
  14. 14.
    Ena J, Dick RW, Jones RN, Wenzel RP (1993) The epidemiology of intravenous vancomycin usage in a University Hospital: a 10-year study. JAMA 269:598–602PubMedCrossRefGoogle Scholar
  15. 15.
    Rubin M, Hathorn, Marshall D et al (1988) Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 108:30–35PubMedGoogle Scholar
  16. 16.
    EORTC International Antimicrobial Therapy Cooperative Group and NCI-CTG (1991) Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 163:951–958CrossRefGoogle Scholar
  17. 17.
    Montecalvo MA, Horowits H, Gedris C et al (1994) Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium in an adult oncology unit. Antimicrob Agents Chemother 38:1363–1367PubMedCrossRefGoogle Scholar
  18. 18.
    Elting LS, Bodey GP, Keefe BH (1992) Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 14:1201–1207PubMedCrossRefGoogle Scholar
  19. 19.
    Marron A, Carratttala J, Gonzalez-Barca E, Fernandz-Sevilla A, Alcaide F, Guidol F (2000) Serious complications of bacteremia caused by viridans streptococci in neutropenic patients with cancer. Clin Infect Dis 31:1126–1130PubMedCrossRefGoogle Scholar
  20. 20.
    Klastersky J, Paesmans M, Rubenstein EB et al (2000) The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying lowrisk febrile neutropenic cancer patients. J Clin Oncol 18:3038–3051PubMedGoogle Scholar
  21. 21.
    Talcott JA, Whalen A, Clark J et al (1994) Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 12:107–114PubMedGoogle Scholar
  22. 22.
    Malik IA, Khan WA, Karim M et al (1995) Feasibility of outpatient management of fever in cancer patients with lowrisk neutropenia: results of a prospective randomized trial. Am J Med 98:224–231PubMedCrossRefGoogle Scholar
  23. 23.
    Freifeld A, Marchigiani D, Walsh T et al (1999) A doubleblind comparison of empirical oral and intravenous antibiotic therapy for low-risk patients with neutropenia during cancer chemotherapy. N Engl J Med 341:305–311PubMedCrossRefGoogle Scholar
  24. 24.
    Kern WV, Cometta A, de Bock R et al from the International Antimicrobial Therapy Cooperative Group of the European Organisation for Research and Treatment of Cancer (1999) Oral versus intravenous empirical antimicrobial therapy for low-r isk patients with neutropenia dur are receiving cancer chemotherapy. N Engl J Med 341: 312–318PubMedCrossRefGoogle Scholar
  25. 25.
    Garcia-Carbonera R, Mayordomo JI, Tornamira MV et al (2001) Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst 93:31–38CrossRefGoogle Scholar
  26. 26.
    Hubel K, Dale D, Engert A, Liles WC (2001) Current status of granulocyte (neutrophil) transfusion therapy for infectious diseases. J Infect Dis 183:321–328PubMedCrossRefGoogle Scholar
  27. 27.
    EORTC International Antimicrobial Therapy Cooperative Group (1989) Empiric antifungal therapy in febrile granulocytopenic patients with cancer. Am J Med 86:668–672CrossRefGoogle Scholar
  28. 28.
    Pizzo PA, Robichard KJ, Gill FA, Witebsky FG (1982) Empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med 72:101–111PubMedCrossRefGoogle Scholar
  29. 29.
    Karp JE, Merz WG, Charache P (1991) Response to empiric amphotericin B during antileukemic therapy-induced granulocytopenia. Rev Infect Dis 13:592–599PubMedCrossRefGoogle Scholar
  30. 30.
    Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC (2000) A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 108:282–289PubMedCrossRefGoogle Scholar
  31. 31.
    Wingard JR, White MH, Anaissie E et al (2000) A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 31:1155–1163PubMedCrossRefGoogle Scholar
  32. 32.
    Wingard JR, Kubilis, Lee L et al (1999) Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 29:1402–1407PubMedCrossRefGoogle Scholar
  33. 33.
    Cagnani PJ, Walsh TJ, Prendergast MM et al (2000) Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 18: 2476–2483Google Scholar
  34. 34.
    Talbot GH, Provencher M, Cassileth PA (1988) Persistent fever after recovery from granulocytopenia in acute leukemia. Arch Intern Med 148:129–135PubMedCrossRefGoogle Scholar
  35. 35.
    Barton TD, Schuster MG (1996) The cause of fever following resolution of neutropenia in patients with acute leukemia. Clin Infect Dis 22:1064–1068PubMedCrossRefGoogle Scholar
  36. 36.
    Johnson S, Gerding DN (1998) Clostridium difficile-associated diarrhea. Clin Infect Dis 26:1027–1036PubMedCrossRefGoogle Scholar
  37. 37.
    Manabe YC, Vinetz JM, Moore RD, Merz C, Charache P, Bartlett JG (1995) Clostridium difficile colitis: an efficient clinical approach to diagnosis. Ann Intern Med 123: 835–840PubMedGoogle Scholar
  38. 38.
    Moir CR, Scudamore CH, Benny WB (1986) Typhlitis: selective surgical management. Am J Surg 151:563–566PubMedCrossRefGoogle Scholar
  39. 39.
    Keidan RD, Fanning J, Gatenby RA, Weese JL (1989) Recurrent typhlitis: a disease resulting from aggressive chemotherapy. Dis Colon Rectum 32:206–209PubMedCrossRefGoogle Scholar
  40. 40.
    Groeger JS, Lucas AB, Thaler HT et al (1993) Infectious morbidity associated with long-term use of venous access devices in patients with cancer. Ann Intern Med 119: 1168–1174PubMedGoogle Scholar
  41. 41.
    Mueller BU, Callender DPE, Marshall D et al (1992) A prospective randomized trial comparing the infectious and noninfectious complications of an externalized catheter versus a subcutaneously implanted device in cancer patients. J Clin Oncol 10:1943–1948PubMedGoogle Scholar
  42. 42.
    Raad II, Davis S, Becker M et al (1993) Low infection rate and long durability of nontunneled silastic catheters. Arch Intern Med 153:1791–1796PubMedCrossRefGoogle Scholar
  43. 43.
    Pearson ML, Hospital Infection Control Practices Advisory Committee (1996) Guideline for prevention of intravascular device-related infections. Infect Control Hosp Epidemiol 17:438–473PubMedCrossRefGoogle Scholar
  44. 44.
    Raad II, Costerton W, Sabharwal et al (1993) Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement. J Infect Dis 168:400–407PubMedCrossRefGoogle Scholar
  45. 45.
    Groeger JS, Lucas AB, Coit D et al (1993) A prospective, randomized evaluation of the effect of silver-impregnated cuffs for preventing tunneled chronic venous access catheter infections in cancer patients. Ann Surg 218:206–210PubMedCrossRefGoogle Scholar
  46. 46.
    Raad II, Davis S, Khan A et al (1992) Impact of central venous catheter removal on the recurrence of catheter-related coagulase-negative staphylococcal bacteremia. Infect Control Hosp Epidemiol 13:215–221PubMedCrossRefGoogle Scholar
  47. 47.
    Dugdale DC, Ramsey PG (1990) Staphylococcus aureus bacteremia in patients with Hickman catheters. Am J Med 89:137–141PubMedCrossRefGoogle Scholar
  48. 48.
    Lecciones JA, Lee JW, Navarro EE et al (1992) Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis 14:875–883PubMedCrossRefGoogle Scholar
  49. 49.
    Raad II, Sabbagh MF (1992) Optimal duration of therapy for catheter-related Staphylococcus aureus bacteremia: a study of 55 cases and review. Clin Infect Dis 14:75–82PubMedCrossRefGoogle Scholar
  50. 50.
    Anaissie EJ, Darouchie RO, Abi-Said D et al (1996) Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 23:964–972PubMedCrossRefGoogle Scholar
  51. 51.
    Edwards JE, Bodey GP, Bowden RA et al (1997) International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 25:43–59PubMedCrossRefGoogle Scholar
  52. 52.
    Wald A, Leisenring W, van Burik JA, Bowden RA (1997) Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 175:1459–1466PubMedCrossRefGoogle Scholar
  53. 53.
    Denning DW (1998) Invasive aspergillosis. Clin Infect Dis 26:781–805PubMedCrossRefGoogle Scholar
  54. 54.
    White MH, Anaissie EJ, Kusne S et al (1997) Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 24:635–642PubMedGoogle Scholar
  55. 55.
    Robertson MJ, Larson RA (1988) Recurrent fungal pneumonias in patients with acute nonlymphocytic leukemia undergoing multiple courses of intensive chemotherapy. Am J Med 84:233–239PubMedCrossRefGoogle Scholar
  56. 56.
    Martino R, Nomdendeu J, Atles A et al (1994) Successful bone marrow transplantation in patients with previous invasive fungal infections: report of four cases. Bone Marrow Transplant 13:265–269PubMedGoogle Scholar
  57. 57.
    Engels EA, Lau J, Barza M (1998) Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 16:1179–1187PubMedGoogle Scholar
  58. 58.
    Bow EJ, Mandell LA, Louie TJ et al (1996) Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented Gram-positive activity on infectious morbidity. Ann Intern Med 125:183–190PubMedGoogle Scholar
  59. 59.
    Carratala J, Fernandez-Sevilla A, Tubau F et al (1995) Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 20:557–560PubMedCrossRefGoogle Scholar
  60. 60.
    Catarrala J, Alcaide F, Fernandez-Sevilla A et al (1995) Bacteremia due to viridans streptococci that are highly resistant to penicillin: increase among neutropenic patients with cancer. Clin Infect Dis 20:1169–1173CrossRefGoogle Scholar
  61. 61.
    Goodman JL, Winston DJ, Greenfield RA et al (1992) A controlled trial of fiuconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326:845–851PubMedCrossRefGoogle Scholar
  62. 62.
    Rotstein C, Bow EJ, Laverdiere M et al (1999) Randomized placebo-controlled trial of fiuconazole prophylaxis for neutropenic caner patients: benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis 28:331–340PubMedCrossRefGoogle Scholar
  63. 63.
    Wingard JR, Merz WG, Rinaldi MG et al (1991) Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 325:1274–1277PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • J. P. Flaherty

There are no affiliations available

Personalised recommendations